MannKind (MannKind) LT-Debt-to-Total-Asset : 0.53 (As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is MannKind LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. MannKind's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.53.

MannKind's long-term debt to total assets ratio declined from Dec. 2022 (0.94) to Dec. 2023 (0.53). It may suggest that MannKind is progressively becoming less dependent on debt to grow their business.

MannKind LT-Debt-to-Total-Asset Historical Data

The historical data trend for MannKind's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MannKind LT-Debt-to-Total-Asset Chart

MannKind Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

1.24

1.10

0.88

0.94

0.53

MannKind Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.94	0.90	0.84	0.80	0.53

MannKind LT-Debt-to-Total-Asset Calculation

MannKind's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	252.624	/	475.198
	=	0.53

MannKind's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	252.624	/	475.198
	=	0.53

MannKind (NAS:MNKD) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

MannKind LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of MannKind's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

MannKind (MannKind) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MannKind Corp (NAS:MNKD) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

NNFN:Germany

Address

1 Casper Street, Danbury, CT, USA, 06810

Website

https://www.mannkindcorp.com

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.

Executives

Michael Castagna	officer: Chief Commercial Officer	25134 RYE CANYON LOOP, SUITE 300, VALENCIA CA 91355
David Thomson	officer: VP & Assoc General Counsel	28903 NORTH AVENUE PAINE, VALENCIA CA 91355
Steven B. Binder	officer: Chief Financial Officer	30930 RUSSELL RANCH ROAD, SUITE 300, WESTLAKE VILLAGE CA 91362
Burkhard Blank	officer: EVP Chief Medical Officer	C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Lauren M Sabella	officer: EVP Chief Operating Officer	C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Sanjay R Singh	officer: EVP Technical Operations	1 CASPER STREET, DANBURY CT 06810
Alejandro Galindo	officer: Chief Commercial Officer	30930 RUSSELL RANCH RD, STE 300, WESTLAKE VILLAGE CA 91362
Stuart A Tross	officer: Corp VP, Chief People Officer	ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Anthony C Hooper	director	AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Jennifer Grancio	director	30930 RUSSELL RANCH ROAD SUITE 300, WESTLAKE VILLAGE CA 91362
Christine Mundkur	director
Sabrina Kay	director	30930 RUSSELL RANCH ROAD, SUITE 300, WESTLAKE VILLAGE CA 91362
David M Kendall	officer: Chief Medical Officer	30930 RUSSELL RANCH ROAD, WESTLAKE VILLAGE CA 91362
Patrick Mccauley	officer: Chief Commercial Officer	30930 RUSSELL RANCH ROAD, SUITE 300, WESTLAKE VILLAGE CA 91362
Barton Courtney	officer: Chief Compliance Officer	30930 RUSSELL RANCH ROAD, WESTLAKE VILLAGE CA 91362